AIM Breakfasts

AIM BREAKFAST – 13th January 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 973

Total number of AIM Companies trading: 951*
* As at 12 January 2017

Dish of the Day:

No AIM Joiners Today

Off the Menu:

No AIM Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 85*

Total number of ISDX Growth Market Companies trading: 82*
* As at 12 January 2017

Dish of the Day:

No NEX Growth Market Joiners Today

Off the Menu:

No NEX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Logicor—Report in City A.M. that Blackstone is aiming to list warehouse business Logicor, which is valued at around €13bn (£11bn), on the London Stock Exchange in 2017.

Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas  exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise.

Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.


Breakfast Buffet

Ariana Resources (AAU.L) 1.9p £15.99m

Ariana has announced an oversubscribed placing raising £900k at 1.6p. The net proceeds of the Placing will be used to advance the Company’s projects outside of Kiziltepe, and to support ongoing working capital requirements of the Group. “Following the recent acquisition of 100% of the 1m oz Salinbas Project and the completion of a highly encouraging scoping study at Tavsan, the funds raised will be utilised to advance these projects in particular.  Both projects require additional value additive work that it is important that we conduct during the winter months and immediately ahead of the exploration field season. Completing this work while Kiziltepe is in the process of entering production, will contribute significantly towards our strategy to enhance our production profile towards 50k oz gold per annum.”

Collagen Solutions (COS.L) 9.38p £10.78m

The developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices, research and in-vitro diagnostics, has been awarded a third Medical Research Scotland Ph.D. studentship, this time in partnership with Professor Elizabeth Tanner, of the School of Engineering, at the University of Glasgow. The project, titled “Collagen Calcium Phosphate Composite Devices for Bone Augmentation”, will investigate the application of collagen fibrils to provide a scaffold for “critical size defects” in bone, which do not heal spontaneously. “Our current pipeline includes a novel bone graft substitute product, addressing a segment of the $1.7 billion end-user bone graft market opportunity. “This programme will ensure further innovation in this field.

Akers Biosicences (AKR.L) 124.5p £9.22m

Further to the public offering announced on January 10, 2017, Joseph Gunnar & Co., LLC, the sole book-running manager for the Offering, has elected to exercise its over-allotment option, pursuant to its underwriting agreement with the Company, to purchase an additional 122,500 common shares from the Company at $1.20 per share with the issuance of a further 61,250 warrants with an exercise price of $1.50.  The gross proceeds from the Offering, are now expected to increase to $2,147,400, before deducting the underwriting discount and estimated offering expenses.  Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers.

Electrical Geodesics (EGI.L) 79p £2.81m

FYDec16 trading update from the neurodiagnostic medical technology company expects $14.3m revenue, an increase of 5% but revenues for H2 some 9% lower than the Company’s record H2 in 2015. A weaker than expected Q4 reflects a significant number of sales opportunities moving into 2017 with customers reporting uncertainties arising from the US election results & the impact on research funding & the likely efforts to repeal the Affordable Care Act. Indications are that a portion of US commercial opportunities expected to close in Q4 will likely finalise in H1 2017. International sales continue to be challenged by dollar strength  but the major markets in the EU and Asia showed growth. “The adoption of dEEG as a standard of care by several European neurology societies will further support continuing clinical growth.”

Manx Telecom (MANX.L) 199p £224.5m

Pre-close trading update from the leading communication solutions provider on the Isle of Man. trading during 2016 has been in line with management expectations with cash flow continuing to support a progressive dividend. Availability of high speed broadband services continues to grow, now reaching 93% of premises, and take up continues to expand with 40% of the broadband customer base now on VDSL or VDSL+. Data centre revenues down largely offset a return to good levels of growth in the Global Solutions business. Expects £10m exceptional costs over 2 years on an enhancement programme. FY16E £81.56 rev, EPS 13.4p, 10.94p div.

Steppe Cement (STCM.L) 16.5p £36.14m

Preliminary update for FYDec16. Revenue down 8% to 17,841 KZT. Volumes down 4%. Prices down 4% mostly due to competition among local companies and the start-up of two dry kilns in  Kazakhstan. Market contracting. The fourth quarter marked a shift in strategy as Steppe Cement tried to maintain higher prices at the expense of market share. The strategy may be revised depending on the overall market reaction and the market share until the high season in 2017. Market share of 17% broadly stable in 2016. FY Dec16E £53m, PBT £3.91m, Div 1.14p.


Iofina (IOF.L) 19.75p £12.73m

Corporate update from the specialists in the exploration and production of iodine and iodine specialty chemical derivatives.  Iofina produced a total of 218.6 MT of crystalline iodine in H2. 2016 total crystalline iodine production was 474.2 MT. As previously announced, the Company experienced lower than expected output from its IOsorb® plants in November and early December due largely to an acceleration of its partners’ fracking operations. More normalised production levels resumed in late DecemberIofina expects to produce 235 – 255 MT of crystalline iodine in H1 2017 from its Oklahoma  plants.  Production revenues are currently held back by low iodine prices, but the chemical processing activity continues to trade successfully.


88 Energy (88E.L) 3.9p £104m

Update on Project Icewine, located onshore North Slope of Alaska. Conventional Prospectivity Review by 88 Energy over Project Icewine complete.    Additional resource potential identified for conventional leads across Project Icewine acreage, based on internal estimates totalling: 710 million barrels of gross mean Prospective Resources (unrisked) -550 million barrels of net mean Prospective Resources to 88 Energy (unrisked). “Whilst the conventional Prospective Resource is very large, it is eclipsed by the potential of the HRZ”  (shale).


Snoozebox Holdings (ZZZ.L) 0.41p £1.21m

Snoozebox will once again be providing accommodation at the Isle of Man TT races being held 27 May to 9 June 2017. Snoozebox will be providing a total of 240 rooms for the duration of the event.  For the fourth year running Snoozebox will be located in Noble’s Park close to the main TT grandstand, start/finish line, paddock and TT hospitality suite, and just minutes from all the action. Adjacent to the hotel is a restaurant, bar and guest lounge. There are no forecasts in the market.


All Star Minerals (NEX:ASMO) 0.125p £1.2m

Quarterly update.  Since the last quarterly update  there has been continued focus on two opportunities for the Company.  Whilst at this time there can be no guarantee as to the outcome of these  opportunities, it provides an indication that the board is proactively looking  to advance All Star. All Star maintains its holding of 5,521,545 shares in NQ Minerals Plc (NQ). The Board of All Star notes progress made by NQ in the last quarter and continues to be encouraged by the developments.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.